Corvus Pharmaceuticals Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Corvus Pharmaceuticals stock.
View analyst ratings for Corvus Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Corvus Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Corvus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its quarterly earnings data on Thursday, October, 29th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.09.
View Corvus Pharmaceuticals' earnings history.

Corvus Pharmaceuticals' stock was trading at $2.71 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CRVS shares have increased by 5.5% and is now trading at $2.86.
View which stocks have been most impacted by COVID-19.

3 brokers have issued 1 year price targets for Corvus Pharmaceuticals' stock. Their forecasts range from $4.00 to $12.00. On average, they anticipate Corvus Pharmaceuticals' stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 179.7% from the stock's current price.
View analysts' price targets for Corvus Pharmaceuticals or view top-rated stocks among Wall Street analysts.

4 employees have rated Corvus Pharmaceuticals CEO Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among Corvus Pharmaceuticals' employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Corvus Pharmaceuticals include RedHill Biopharma (RDHL), Sesen Bio (SESN), Oncorus (ONCR), iBio (IBIO), Graybug Vision (GRAY), Alpine Immune Sciences (ALPN), TFF Pharmaceuticals (TFFP), NextCure (NXTC), BELLUS Health (BLU), VistaGen Therapeutics (VTGN), Theratechnologies (THTX), Ampio Pharmaceuticals (AMPE), Kezar Life Sciences (KZR), Arbutus Biopharma (ABUS) and Kamada (KMDA).
View all of CRVS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).

(CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Corvus Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.84%), CHI Advisors LLC (1.75%), BlackRock Inc. (0.25%), Truist Financial Corp (0.07%) and Golden Green Inc. (0.07%). Company insiders that own Corvus Pharmaceuticals stock include Holdings A/S Novo, Leiv Lea, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller.
View institutional ownership trends for Corvus Pharmaceuticals.

CRVS stock was sold by a variety of institutional investors in the last quarter, including CHI Advisors LLC, BlackRock Inc., and Renaissance Technologies LLC.
View insider buying and selling activity for Corvus Pharmaceuticals or view top insider-selling stocks.

CRVS stock was bought by a variety of institutional investors in the last quarter, including Truist Financial Corp, and Golden Green Inc.. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Leiv Lea, Orbimed Advisors Llc, Peter A Thompson, and Richard A Md Miller.
View insider buying and selling activity for Corvus Pharmaceuticals or or view top insider-buying stocks.

Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRVS stock can currently be purchased for approximately $2.86.

Corvus Pharmaceuticals has a market capitalization of $80.26 million. The company earns $-46,670,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis.

Corvus Pharmaceuticals employs 52 workers across the globe.

The official website for Corvus Pharmaceuticals is www.corvuspharma.com.

Corvus Pharmaceuticals is headquartered at 863 Mitten Road Suite102, BURLINGAME CA, 94010.

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]